Toronto, ON – Princess Margaret Hospital (PMH) has been awarded a $3 million US National Cancer Institute Phase I grant headed by Senior Scientist Dr Lillian Siu, co-director of the Robert and Maggie Bras and Family New Drug Development Program
The funding – of which only two new applications were funded in this cycle – was awarded to PMH to expedite access to and evaluation of novel anti-cancer agents for patients; to optimize clinical trial design for new drugs and treatments; and to characterize the effects of new drugs on their targets with clinically relevant endpoints, through the integration of suitable biochemical, pathological, immunological, molecular, and/or imaging methods.
“This is a huge endorsement of the new drug development program at PMH, and solidifies our reputation as one of the leading drug development centres in the world,” says Dr Malcolm Moore, head of the division of medical oncology and hematology at the hospital.
The grant will ensure PMH patients have access to the most promising treatments for cancer while helping to continue bolster clinical and translational research at the institute.
Have your say: